What is Compass Therapeutics Inc. (CMPX) stock price today?

Compass Therapeutics Inc. (CMPX) currently trades at $1.67 per share. The stock has a market capitalization of $300.75M and a P/E ratio of —x.

Is CMPX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Compass Therapeutics Inc. has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is —.

Is Compass Therapeutics Inc. financially healthy?

Compass Therapeutics Inc.'s Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of — places it in the —.

CMPX

Compass Therapeutics Inc.

NASDAQ: CMPX · HEALTHCARE · BIOTECHNOLOGY

$1.67

-9.24% today

Updated 2026-04-29

Market cap

$300.75M

P/E ratio

—

P/S ratio

269.28x

EPS (TTM)

$-0.42

Dividend yield

—

52W range

$2 – $7

Volume

6.7M

Market cap

$300.75M

P/E ratio

—

P/S ratio

269.28x

EPS (TTM)

$-0.42

Dividend yield

—

52W range

$2 – $7

Volume

6.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$11.25

+573.65%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy13 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-13.25M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$850000.00	$0.00	$0.00
Net income	$-39.23M	$-42.49M	$-49.38M	$-66.49M	$-15.72M
EPS	—	—	—	—	$-0.42
Free cash flow	$-34.34M	$-40.65M	$-44.90M	$-49.17M	$-13.25M
Profit margin	—	—	-5,808.82%	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-08	SCHUETZ, THOMAS J.	Sale	36,687	$6.52
2026-01-09	SCHUETZ, THOMAS J.	Sale	46,777	$5.35
2026-01-02	SIRARD, CYNTHIA	Buy	1,000,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CMPX	$300.75M	31	4.3	3.0	5.0	5.5	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Compass Therapeutics Inc. trades at $1.67. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score.

Frequently asked questions

What is Compass Therapeutics Inc.'s stock price?

Compass Therapeutics Inc. (CMPX) trades at $1.67.

Is Compass Therapeutics Inc. overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Compass Therapeutics Inc. (CMPX)?

The analyst target price is $11.25, representing +573.7% upside from the current price of $1.67.

Piotroski F-Score?

1/9 — weak financial health.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio269.28x

ROE-41.30%

Beta1.30

50D MA$5.30

200D MA$4.62

Shares out0.18B

Float0.12B

Short ratio—

Avg volume6.7M

Performance

1 week-65.41%

1 month-63.92%

3 months-70.13%

YTD-65.74%

1 year—

3 years—

5 years—

Compare

CMPX vs LLY →CMPX vs JNJ →CMPX vs ABBV →Stock screener →